Skip to main content
EC

Emmanuel Chartier-Kastler

Biography​

Emmanuel Chartier-Kastler is a professor of urology at Sorbonne University and heads the urology service at Pitié-Salpêtrière Hospital in Paris.12 He received his medical degree from Paris 6 University in 1989 and was a fellow and assistant professor in the urology department at Pitié-Salpêtrière from 1992 to 1998.3 He served as secretary general of the French Association of Urology from 2004 to 2007.4

Contributions​

His cited papers address neuro-urologic bladder management and urinary continence, including augmentation cystoplasty, ileal diversion, botulinum toxin treatment, and artificial urinary sphincters.56789

Cited on WARWIKI

15 publications with Emmanuel Chartier-Kastler as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. Biardeau X, Chartier-Kastler E, Rouprêt M, Phé V. "Risk of malignancy after augmentation cystoplasty: a systematic review." Neurourol Urodyn. 2016;35(6):675–682. doi
    Cited on: Endoscopy — Cystoscopy & Ureteroscopy · Augmentation Cystoplasty · Ileocecal Cystoplasty (Ileocecocystoplasty)
  2. Lenfant L, Taillé Y, Chartier-Kastler E, et al. Artificial Urinary Sphincter Implants in Men: A National Health Care Data System-Based Study to Assess Reinterventions in France. The Journal of Urology. 2025;213(2):217-227. doi
    Cited on: Artificial Urinary Sphincter (Device) · Artificial Urinary Sphincter (Procedure)
  3. Grilo N, Chartier-Kastler E, Grande P, et al. "Robot-Assisted Supratrigonal Cystectomy and Augmentation Cystoplasty With Totally Intracorporeal Reconstruction in Neurourological Patients." Eur Urol. 2021;79(6):858–865. doi
    Cited on: Robotic Reconstructive Applications · Supratrigonal Cystectomy with Augmentation Cystoplasty
  4. Tullman M, Chartier-Kastler E, Kohan A, et al. "Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS." Neurology. 2018;91(7):e657–e665. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct) · Multiple Sclerosis
  5. Rovner E, Kohan A, Chartier-Kastler E, et al. "Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment." J Urol. 2016;196(3):801–808. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct) · Intradetrusor OnabotulinumtoxinA
  6. Bazinet A, Chartier-Kastler E, Gazdovich S. Artificial Urinary Sphincter for Female Stress Urinary Incontinence. In: Martins FE, Holm HV, Sandhu JS, McCammon KA, eds. Female Genitourinary and Pelvic Floor Reconstruction. Springer; 2023:407-436.
    Cited on: Artificial Urinary Sphincter (Procedure)
  7. Ismail S, Karsenty G, Chartier-Kastler E, et al. "Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review." Neurourol Urodyn. 2018;37(4):1386-1395. doi
    Cited on: Spinal Cord Injury
  8. Matzel KE, Chartier-Kastler E, Knowles CH, et al. "Sacral Neuromodulation: Standardized Electrode Placement Technique." Neuromodulation. 2017;20(8):816-824. doi
    Cited on: Sacral Neuromodulation
  9. McVary KT, Roehrborn CG, Chartier-Kastler E, et al. "A multicenter, randomized, double-blind, placebo-controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia." J Urol. 2014;192(1):150–156. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  10. Phé V, Nguyen K, Rouprêt M, Cardot V, Parra J, Chartier-Kastler E. "A Systematic Review of the Treatment for Female Stress Urinary Incontinence by ACT Balloon Placement (Uromedica, Irvine, CA, USA)." World J Urol. 2014;32(2):495–505. doi
    Cited on: Adjustable Continence Devices
  11. Marberger M, Chartier-Kastler E, Egerdie B, et al. "A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia." Eur Urol. 2013;63(3):496–503. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  12. Yates DR, Phé V, Rouprêt M, Vaessen C, Parra J, Mozer P, Chartier-Kastler E. Robot-assisted laparoscopic artificial urinary sphincter insertion in men with neurogenic stress urinary incontinence. BJU Int. 2013;111(7):1175-1179. doi
    Cited on: Artificial Urinary Sphincter (Procedure)

Footnotes​

  1. https://fc.sorbonne-universite.fr/pdf/fiche/. Accessed October 2026. ↩

  2. Urologie. Faculté de Médecine. Accessed October 2026. ↩

  3. DocumentsDownload.aspx. Accessed October 2026. ↩

  4. Emmanuel Chartier-Kastler. Formation Continue Sorbonne Université. Accessed October 2026. ↩

  5. Biardeau X, Chartier-Kastler E, Rouprêt M, Phé V. "Risk of malignancy after augmentation cystoplasty: a systematic review." Neurourol Urodyn. 2016;35(6):675–682. doi:10.1002/nau.22775 ↩

  6. Tullman M, Chartier-Kastler E, Kohan A, et al. "Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS." Neurology. 2018;91(7):e657–e665. doi:10.1212/wnl.0000000000005991 ↩

  7. Rovner E, Kohan A, Chartier-Kastler E, et al. "Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment." J Urol. 2016;196(3):801–808. doi:10.1016/j.juro.2016.04.046 ↩

  8. Lenfant L, Taillé Y, Chartier-Kastler E, et al. Artificial Urinary Sphincter Implants in Men: A National Health Care Data System-Based Study to Assess Reinterventions in France. The Journal of Urology. 2025;213(2):217-227. doi:10.1097/ju.0000000000004285 ↩

  9. Grilo N, Chartier-Kastler E, Grande P, et al. "Robot-Assisted Supratrigonal Cystectomy and Augmentation Cystoplasty With Totally Intracorporeal Reconstruction in Neurourological Patients." Eur Urol. 2021;79(6):858–865. doi:10.1016/j.eururo.2020.08.005 ↩